Table 1.
Clinical and Procedural Features in Patients With and Without Postprocedural Dialysis in the Derivation Group
| No dialysis (n=6714) | Postprocedural dialysis (n=51) | P value | |
|---|---|---|---|
| Age, y | 81.7±6.3 | 79.3±7.8 | 0.04 |
| Male sex, % | 47.3 | 66.7 | 0.007 |
| BMI | 26.7±4.8 | 26.8±3.6 | 0.92 |
| Diabetes, % | 29.4 | 45.1 | 0.02 |
| Hypertension, % | 83.0 | 81.6 | 0.82 |
| Smoking, % | 17.3 | 15.7 | 0.91 |
| NYHA III–IV, % | 75.2 | 86.0 | 0.10 |
| Coronary artery disease | 33.9 | 49.0 | 0.03 |
| Prior MI, % | 14.9 | 25.5 | 0.06 |
| Prior PCI, % | 24.9 | 28.6 | 0.62 |
| Prior CABG, % | 12.3 | 26.5 | 0.007 |
| Prior CVA, % | 11.3 | 18.4 | 0.12 |
| PAD, % | 15.9 | 34.7 | 0.001 |
| Active cancer, % | 6.1 | 1.9 | 0.42 |
| Porcelain aorta, % | 4.7 | 8.3 | 0.24 |
| AF, % | 27.2 | 27.5 | 0.92 |
| Anemia, % | 23.9 | 49.0 | <0.0001 |
| Creatinine, mg/dL | 1.2±0.6 | 1.8±1.5 | 0.002 |
| Creatinine clearance | 53±24 | 41±18 | <0.0001 |
| CKD | <0.0001 | ||
| CKD stage 5 (%) | 3.3 | 6.1 | |
| CKD stage 4 (%) | 9.5 | 22.5 | |
| CKD stage 3 (%) | 54.3 | 57.1 | |
| CKD stage 2 (%) | 25.5 | 12.3 | |
| CKD stage 1 (%) | 7.4 | 2.0 | |
| Hemoglobin, g/dL | 12.2±1.7 | 11.2±2.0 | 0.002 |
| STS score | 5.5±4.7 | 9.4±6.9 | 0.001 |
| Euroscore II | 5.8±5.5 | 13.0±15.9 | 0.004 |
| EF, % | 54.4±11.5 | 53.4±13.9 | 0.60 |
| PG mean, mm Hg | 47±15 | 45±15 | 0.31 |
| Aspirin, % | 54.4 | 59.5 | 0.62 |
| P2Y12 inhibitor, % | 21.2 | 21.6 | 0.92 |
| DAPT, % | 14.8 | 19.4 | 0.45 |
| VKA, % | 21.1 | 26.5 | 0.41 |
| Apical access, % | 5.3 | 33.3 | <0.0001 |
| No femoral access, % | 8.2 | 37.3 | <0.0001 |
| Femoral access, % | 91.8 | 62.7 | <0.0001 |
| Corevalve, % | 44.9 | 41.9 | 0.76 |
| Edwards valve, % | 37.2 | 41.2 | 0.56 |
| Valve size | 26.5±2.7 | 26.3±2.5 | 0.65 |
| Valve in valve, % | 2.7 | 5.9 | 0.16 |
| Paravalvular leak | 0.69 | ||
| No paravalvular leak, % | 71.6 | 72.5 | |
| Paravalvular leak I, % | 23.9 | 21.6 | |
| Paravalvular leak II, % | 3.9 | 3.9 | |
| Paravalvular leak III, % | 0.5 | 2.0 | |
| Paravalvular leak, % | 0.1 | 0 | |
| Volume contrast, mL | 194±91 | 262±114 | 0.002 |
| Pacemaker, % | 12.7 | 7.4 | 0.40 |
| Major vascular complications, % | 7.1 | 25.5 | <0.0001 |
| Minor vascular complication, % | 7.9 | 7.8 | 0.98 |
| Transfusion, % | 16.8 | 61.4 | <0.0001 |
| Treatment at discharge | |||
| Single antiplatelet, % | 25.7 | 23.5 | |
| DAPT, % | 28.5 | 21.6 | |
| Oral anticoagulants, % | 25.8 | 29.4 | |
| 30‐d mortality, % | 2.3 | 24.0 | <0.0001 |
| 30‐d stroke/TIA, % | 1.4 | 3.9 | 0.28 |
AF indicates atrial fibrillation; BMI, body mass index; CABG, coronary artery bypass graft; CKD, chronic kidney disease; CVA, cerebrovascular accident; DAPT, dual antiplatelet therapy; EF, ejection fraction; MI, myocardial infarction; NYHA, New York Heart Association; PAD, peripheral artery disease; PCI, percutaneous coronary intervention; PG, pressure gradient; STS, Society of Thoracic Surgeons; TIA, transient ischemic attack; and VKA, vitamin K antagonist.